While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

The administration might be launching a campaign specifically targeting such products. This would follow Monday's executive ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...